Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 99-104

  Hilger, Ralf Axel ^a   Harstrick, Andreas ^a   Eberhardt, Wilfried ^a   Oberhoff, Carsten ^a   Skorzec, Matthias ^a   Baumgart, Joachim ^b   Seeber, Siegfried ^a   Scheulen, Max Ernst ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MEDAC GMBH   (Germany)

Author keywords

Dihydroxybusulfan; Infusion; Patient; Pharmacokinetics; Treosulfan

Indexed keywords

TREOSULFAN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 0031831211     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050791     Document Type: Article

References (27)

1. Abdulla U, Makanji HH, Cox C, Alsaidi TK, White WF, Masding JE (1982) Intravenous treosulfan in advanced ovarian cancer: a multicenter pilot study. Br J Cancer 46: 500
2. Breitbach GP, Villena C, Schwickerath J, Kunz T, Hurst U, Schmidt-Rhode P, Friederich EJ, Artmeyer E, Schröder M, Eberl M, Franck J, Meinen K, Schiller S, Wernicke K, Sasse G, Schmid H, Bastert G (1994) Treosulfan bei fortgeschrittenem Ovarialcarcinom: Eine Phase III-studie. Arch Gynecol Obstet 225 [Suppl 1]: 80
3. Brookes P, Lawley PD (1961) The reaction of mono- and di-functional alkylating agents with nucleic acids. Biochem J 80: 496-503
4. David W, Ross WCJ (1963) The formation of epoxides from cytotoxic polyol methanesulphonates under physiological conditions. Biochem Pharmacol 12: 915-917
5. Duncan ID, Clayton LA (1985) Combination chemotherapy of ovarian carcinoma with cis-platinum and treosulfan a phase II study. Br J Obstet Gynaecol 92: 762-767
6. Feit PW (1961) Stereoisomere 1,4-di-O-methansulfonyl-butane-1,2,3,4-tetrole. Tetrahedron Lett 20: 716-717
7. Feit PW (1964) 1,4-Bismethanesulfonates of the stereoisomeric butanetetraols and related compounds. J Med Chem 7: 14-17
8. Feit PW, Rastrup-Andersen N, Matagne R (1970) Studies on epoxide formation from (2S,3S)-threitol-1,4-bismethane-sulfonate. The preparation and biological activity of (2S, 3S-1,2-epoxy-3,4-butanediol-4-methanesulfonate. J Med Chem 13: 1173-1175
9. Fennelly J (1977) Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma. Br J Obstet Gynaecol 84: 300-303
10. Harstrick A, Wilke H, Eberhardt W, Klaassen U, Strumberg D, Korn M, Scheulen ME, Baumgart J, Seeber S (1996) A phase I dose escalation trial of intravenous treosulfan in re-fractory cancer. Onkologie 19: 153-156
11. Hartley JA, O'Hare CC, Baumgart J (1998) DNA alkylation and interstrand crosslinking by treosulfan. Br J Cancer (in press)
12. Heinzel G, Woloszczak R, Thomann P (1993) TOPFIT: version 2.0: pharmacokinetic and pharmacodynamic data analysis system for the PC. Fischer VCH, Stuttgart
13. Hilger RA, Harstrick A, Oberhoff C, Baumgart J, Schindler AE, Seeber J, Scheulen ME (1996) Phase I and pharmacokinetic investigation of high-dose treosulfan i.v. with autologous stem cell support in patients with solid tumors. Ann Hematol 73 [Suppl II]: A48
14. Köpf-Maier P (1996) Titanocene dichloride and treosulfan are active against human renal cell carcinoma xenografts. Proc Am Assoc Cancer Res 37: 389
15. Köpf-Maier P, Saß G (1992) Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother Pharmacol 31: 103-110
16. Köpf-Maier P, Saß G (1996) Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol 37: 211-221
17. Lundvall F (1973) Treosulfan in the treatment of ovarian carcinoma. Acta Obstet Gynecol Scand 22 [Suppl]: 3-11
18. Masding J, Sarkar TK, White WF, Barley VL, Chawla SL, Boesen E, Rostom AY, Menday AP (1990) Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol 97: 342-351
19. Meden H, Wittkopp Y, Kuhn W (1997) Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Anticancer Res 17: 2221-2224
20. Merkle E, Bähr I, Bühner M, Martus P, Lang N (1993) Therapie des fortgeschrittenen Ovarialkarzinoms mit Cisplatin und Treosulfan. Tumordiagn Ther 14: 175-180
21. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
22. O'Hare CC, Baumgart J, Hartley JA (1997) DNA alkylation and interstrand crosslinking by treosulfan. Br J Cancer 75 [Suppl 1]: 21
23. Runowicz CD, Fields AL, Goldberg GL (1995) Promising new therapies in the treatment of advanced ovarian cancer. Cancer 76: 2028-2033
24. Warwick GP (1963) The mechanism of action of alkylating agents. Cancer Res 23: 1315-1333
25. Welsh J, Stuart JFB, Soukop M, Cunningham D, Blackie R, Sangster G, Calman KC (1982) The pharmacokinetics of oral and iv treosulfan. Br J Cancer 46: 467
26. White FR (1962) L-Threitol dimethanesulfonate. Cancer Chemother Rep 24: 95-97
27. Zhu S, Zeiger E (1993) Mutagenicity of the human carcinogen treosulphan and its hydrolysis product DL-1,2,3,4-diepoxybutane in mammalian cells. Environ Mol Mutagen 21: 95-99